anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This investigation examined the potential of ginsenoside Rg3 in addressing traumatic brain injury (TBI). A TBI mouse model underwent treatment with ginsenoside Rg3 and nicotinamide (NAM). Neurological and motor functions were assessed using modified neurological severity score and rotarod tests. Brain water content in mice was detected. Primary mouse microglia were exposed to lipopolysaccharide (LPS), ginsenoside Rg3, and NAM. Nissl and immunofluorescence staining were utilized to investigate hippocampal damage, and localization of P65, Iba1 and INOS in microglia. Hippocampal neurons were grown in a culture medium derived from microglia. CCK-8 and TUNEL assays were employed to evaluate the viability and apoptosis of hippocampal neurons. Proinflammatory factors and proteins were tested using ELISA, western blot and immunofluorescence staining. As a result, ginsenoside Rg3 enhanced neurological and motor functions in mice post-TBI, reduced brain water content, alleviated hippocampal neuronal neuroinflammation and damage, activated SIRT1, and deactivated the NF-kB pathway. In LPS-stimulated microglia, ginsenoside Rg3 diminished inflammation, activated SIRT1, deactivated the NF-kB pathway, and facilitated nuclear localization of P65 and co-localization of Iba1 and INOS. The effects of ginsenoside Rg3 were countered by NAM in both TBI mice and LPS-stimulated microglia. Hippocampal neurons cultured in a medium containing LPS, ginsenoside Rg3, and NAM-treated microglia showed improved viability and reduced apoptosis compared to those cultured in a medium with LPS and ginsenoside Rg3-treated microglia alone. Ginsenoside Rg3 was effective in reducing neuroinflammation and damage in hippocampal neurons following TBI by modulating the SIRT1/NF-kB pathway, suggesting its potential as a therapeutic agent for TBI.
One of the most important neurological consequences following Traumatic Brain Injury (TBI) is the development of post traumatic epilepsy (PTE), which accounts for 5% of all epilepsy etiologies in the general population. This makes TBI one of the most important causes of secondary epilepsy, overcoming other causes such as infections, drug abuse or familiar history of epilepsy. The occurrence of spontaneous epileptic seizures after TBI, mostly starting in the first 2 years after moderate or severe TBI, might be as high as 86%, specially in those with a single acute symptomatic seizure, with remission rates of 25-40%. The causative relationship between TBI and epilepsy, as well as other types of epilepsy in general, are still not completely understood and PTE is not yet preventable.

The therapeutic approach indicated for TBI may involve medications, surgical procedures or both, with no effective therapeutic intervention to reduce its occurrence. Several experimental studies in animal models have shown that drugs, which modify processes of neuronal plasticity, have the potential to modify the natural course of PTE. Among these, biperiden (anti-cholinergic indicated for Parkinson's disease) has shown reduction in the incidence and intensity of spontaneous epileptic seizures and also delayed their occurence in animal epilepsy model. Thus Biperiden would be an excellent candidate for an antiepileptogenic agent. It is intended here to test its effectiveness and safety in adult patients, victims of moderate and severe TBI. Patients will be randomized to receive 5 mg of Biperiden iv, diluted in 100 ml of 0.9% saline (treatment group) or 1 mL of sterile vehicle (sodium lactate, lactic acid, sodium hydroxide and water for injections) diluted in 100 mL of 0,9% saline (placebo group), every 6 hours for 10 days after TBI. Prospectively, patients will be followed up for two years, on periodic visits to assess the development of epileptic seizures. Other factors that might have benefits with the treatment, such as epileptiform abnormalities, genetic markers and neuropsychological aspects, will also be evaluated. The results could be important for a better comprehension of basic mechanisms of epilepsy development. Side effects of Biperiden use, at high doses during a short period of time, will be measured. If Biperiden is efficient and safe, it will certainly be a low-cost option for Brazilian public health system (SUS).
BACKGROUND: Individualizing and optimizing treatment of relapsing-remitting multiple sclerosis patients is a challenging problem, which would benefit from a clinically valid decision support. Stühler et al. presented black box models for this aim which were developed and internally evaluated in a German registry but lacked external validation.
METHODS: In patients from the French OFSEP registry, we independently built and validated models predicting being free of relapse and free of confirmed disability progression (CDP), following the methodological roadmap and predictors reported by Stühler. Hierarchical Bayesian models were fit to predict the outcomes under 6 disease-modifying treatments given the individual disease course up to the moment of treatment change. Data was temporally split on 2017, and models were developed in patients treated earlier (n = 5517). Calibration curves, discrimination, mean squared error (MSE) and relative percentage of root MSE (RMSE%) were assessed by external validation of models in more-recent patients (n = 3768). Non-Bayesian fixed-effects GLMs were also applied and their outcomes were compared to these of the Bayesian ones. For both, we modelled the number of on-therapy relapses with a negative binomial distribution, and CDP occurrence with a binomial distribution.
RESULTS: The performance of our temporally-validated relapse model (MSE: 0.326, C-Index: 0.639) is potentially superior to that of Stühler's (MSE: 0.784, C-index: 0.608). Calibration plots revealed miscalibration. Our CDP model (MSE: 0.072, C-Index: 0.777) was also better than its counterpart (MSE: 0.131, C-index: 0.554). Results from non-Bayesian fixed-effects GLM models were similar to the Bayesian ones.
CONCLUSIONS: The relapse and CDP models rebuilt and externally validated in independent data could compare and strengthen the credibility of the Stühler models. Their model-building strategy was replicable.
PURPOSE: A cosmetic composition containing Benincasa hispida THUNB. extract is provided to ensure skin whitening with minimized side effect. CONSTITUTION: A cosmetic composition for skin whitening contains Benincasa hispida THUNB. extract. A method for preparing the extract comprises: a step of cutting out the flower stalk of Benincasa hispida THUNB. in a circular form; a step of collecting 1/2 number of seeds of Benincasa hispida THUNB. and separately drying the seeds; a step of adding 250-500g of Nelumbo nucifera GAERTN. each 200-400g of Artemisia princeps, purslane, Houttuynia cordata, Broussonetia Kazinoki, and ginseng, each 150-300g of Glycyrrhizae radix and Menthae Herba, and Chrysanthemi Flos, and 100-200g of Chaenomeles sinensis (Thouin) Koehne into the body of Benincasa hispida THUNB.(S1); a step of adding 250-500g of malt, 150-300g of black sugar, and 2.25-4.5 L of grain wine(S2); a step of applying dough prepared by mixing germanium and loess in a certain ratio and covering with Hanji(Korean traditional paper)(S3); a step of heating in a Hwangtobang(room made of loess) at 25-50°C for 4-8 days(S4); a step of juicing the Benincasa hispida THUNB.(S5); a step of pulverizing dried Benincasa hispida THUNB. seeds, each 150-300g of mung beans, silk worm, and pearl powder, 200-400g of bay salt, and 150-300g of boric acid; and a step of mixing 20-40 L of distilled water, 96-98 wt% of prepared mixture, and 2-4 wt% of extract and stirring(S6).
OBJECTIVES: Diallyl disulfide (DADS) is a natural organosulfur compound found in garlic and related plants with various pharmacologic effects. However, whether DADS improves obesity-induced insulin resistance (IR) and its underlying mechanisms remain unclear. The aim of this study was to investigate the effects of DADS on systemic IR in high-fat diet-induced obese mice.
METHODS: To induce obesity, 8-wk-old male C57BL/6J mice were fed a high-fat diet (60% fat/kcal). The mice were assigned to three weight-matched groups: control (CON, n = 8), low-dose DADS (DADS-L, n = 8), and high-dose DADS (DADS-H, n = 9). The treated mice were orally administered DADS (25 or 100 mg/kg) 5 d/wk for 8 wk. At 15 wk of age, an intraperitoneal glucose tolerance test (GTT) and insulin tolerance test (ITT) were performed. Twenty-four hours after the final administration of DADS, epididymal fat and the liver were sampled after a 5-h fast.
RESULTS: DADS administration significantly attenuated body and fat weight gains during the experimental period. Additionally, systemic IR, as evaluated by ITT, was significantly improved by DADS administration in a dose-dependent manner. High-dose DADS administration significantly decreased liver triacylglycerol levels. Moreover, high-dose DADS administration decreased the c-Jun N-terminal kinase (JNK) phosphorylation and significantly increased heat shock protein 72 expression in the liver.
CONCLUSIONS: The results of this study suggested that DADS administration alleviated systemic IR in obese mice. This may be associated with decreased hepatic fat accumulation and a heat shock protein 72-mediated decrease in JNK activity in the liver.
The invention discloses a FSBM recombinant protein for conferring protection against group C streptococcus infection in an animal subject, comprising: a first peptide fragment, having an amino acid sequence set forth as SEQ ID NO. 5; a second peptide fragment, having an amino acid sequence set forth as SEQ ID NO. 6; a third peptide fragment, having an amino acid sequence set forth as SEQ ID NO. 7; and a fourth peptide fragment, having an amino acid sequence set forth as SEQ ID NO. 8. The invention also discloses a method of protecting an animal subject against group C streptococcus infection.
Starting doses of danicopan ranged from 100 to 150 milligrams (mg) three times daily (TID), with subsequent dose escalation up to 200 mg TID based on response (clinical and biochemical) for 28 days (Part 1). Participants with reductions in lactate dehydrogenase (LDH) meeting specified criteria were offered continued dosing beyond Day 28, for up to 8 additional weeks (Part 2).
FIELD: veterinary science, in particular, psoroptos control of farm animals. SUBSTANCE: concentrate includes active sulfur-containing substance of phiophenic row and filler (solvent and emulsifier). Used as a sulfur-containing component is di-, trialkyl homologs or functional derivatives of phiophenic row in the amount of 40-50 mas.%, filler, the balance. Besides, used as a filler, is mixture of solvent neophrase and surface-active substance in ratio 1.0-1.2:1. Other version of concentrate additionally contains camphor oil in the amount of 0.5-1.5 mas.% as an active additive. Sanitation of infected animals and treatment of their habitats are conducted with proposed concentrate. EFFECT: increased number of remedies for psoroptos control with low toxicity; reduced expenditure of active substance due to introduction of active additive. 3 cl, 2 tbl, 6 expn
During or immediately after the administration of Cyclophosphamide Tablets, adequate amounts of fluid should be ingested or infused to force diuresis in order to reduce the risk of urinary tract toxicity. Therefore, 

Cyclophosphamide Tablets should be taken in the morning.

Cyclophosphamide Tablets should be swallowed whole. The tablets should not be chewed or crushed. 

Cyclophosphamide Tablets is a cytotoxic drug. Follow applicable special handling and disposal procedures.1 Exposure to broken tablets should be avoided. If contact with broken tablets occurs, wash hands immediately and thoroughly.
Methods and systems for simulating training and subpopulations and selecting training scenarios for neurodevelopmental disorders such as autism spectrum disorder (ASD) are described herein. Population data may be received. Skill data indicating skills associated with one or more behaviors exhibited by individuals with one or more neurodevelopmental disorders may be received. Behavioral goals may be identified. Scenario data indicating a plurality of different training scenarios may be generated. Efficacy data may be generated by estimating a probability that skills would be trained by a given training scenario. Estimated clinical success data may be generated by simulating, for each training scenario and for each subject subpopulation, a degree of behavioral change. A combination of a first subject subpopulation and a first training scenario may be selected. The first training scenario may be associated with training a plurality of different skills.
WHEREIN N IS EQUAL TO 0 OR 1, THE SULFUR ATOM BEING ATTACHED TO THE N-oxypyridyl nucleus in a position ortho or para to the NO group, and R1 represents hydrogen, -COR2 or -SO2R2 wherein R2 is alkyl having 1-4 carbon atoms, phenyl or tolyl; B. THE METAL COMPLEX OF THE COMPOUND IN (A) WHEN R1 is hydrogen; and C. THE METAL SALT OF THE COMPOUND IN (A) WHEN R1 is -COR2 or SO2R2. These derivatives are usefully employed in compositions for application to the hair, scalp or skin in order to combat the greasy and unaesthetic appearance of the hair and scalp and to counteract the formation of body odours of skin. The composition includes the said derivative of pyridine together with an appropriate carrier including, for instance, water, lower alkanol, an aqueous solution of a lower alkanol, a detergent and a cosmetic powder. The said derivative of pyridine can be included in such compositions in amounts ranging from about 0.0110 percent by weight thereof. N-oxypyridyl derivative selected from the group consisting of A. A COMPOUND OF THE FORMULA
Patients at Charite, with lower limb surgery undergoing a protective performed ultrasound guided femoral nerve block. N=15.
Following baseline evaluation, participants in this group will undergo weekly monitoring of insomnia and suicidal ideation for 8 weeks. Participants will continue whatever treatments they are currently receiving, but will receive no specific instructions or behavioral interventions for insomnia. After the interim assessment, participants will then crossover to receive digital Cognitive Behavioral Therapy for Insomnia.
This study aims to evaluate the effect of rapid maxillary expansion using the bonded Hyrax expander combined with low level Laser therapy versus rapid maxillary expansion alone. The investigators intend to recruit sixty subjects of both sexes, between the age of 7 and 14 years. Patients with posterior crossbites and patent Mid-palatal sutures will be randomized into one of the two groups of treatment. Full orthodontic records will be collected and the standard orthodontic radiographs will be replaced by cone beam computer tomographic images. The records will be taken before the maxillary expansion and after 6 months of retention. The skeletal, dentoalveolar, and soft tissue effects of the two interventions will be compared.
PURPOSE:To provide the titled remedy composed of a mixture obtained by grinding rice bran together with nearly the same weight of garlic, or composed of the concentrated extract of the mixture. CONSTITUTION:A 1:1 (weight ratio) mixture of rice bran and garlic is ground to obtain a remedy for the diseases such as foot trychophytosis, (athlete's foot), tinea trichophytia (ringworm), etc. caused by a trychophyton which is a kind of mold. It can be applied to various symptoms of foot trychophytosis (e.g. vessicle, sore, corneous, nail, etc.). The above components are absolutely ineffective when used separately; however, high additive effect can be attained by the combination of the components to exhibit a remarkably high drug action. The mixture obtained by grinding both components can be used as it is (in the form of ointment) or as an extract (liquid) with water, and the same drug action can be obtained in both cases.
BACKGROUND: Duplications on the short arm of chromosome X, including the gene NR0B1, have been associated with gonadal dysgenesis and with male to female sex reversal. Additional clinical manifestations can be observed in the affected patients, depending on the duplicated genomic region. Here we report one of the largest duplications on chromosome X, in a Lebanese patient, and we provide the first comprehensive review of duplications in this genomic region.
CASE PRESENTATION: A 2-year-old female patient born to non-consanguineous Lebanese parents, with a family history of one miscarriage, is included in this study. The patient presents with sex reversal, dysmorphic features, optic atrophy, epilepsy, psychomotor and neurodevelopmental delay. Single nucleotide variants and copy number variants analysis were carried out on the patient through exome sequencing (ES). This showed an increased coverage of a genomic region of around 23.6 Mb on chromosome Xp22.31-p21.2 (g.7137718-30739112) in the patient, suggestive of a large duplication encompassing more than 60 genes, including the NR0B1 gene involved in sex reversal. A karyotype analysis confirmed sex reversal in the proband presenting with the duplication, and revealed a balanced translocation between the short arms of chromosomes X and 14:46, X, t(X;14) (p11;p11) in her/his mother.
CONCLUSIONS: This case highlights the added value of CNV analysis from ES data in the genetic diagnosis of patients. It also underscores the challenges encountered in announcing unsolicited incidental findings to the family.
More than 80,000 Canadian children undergo surgery each year. Despite evidence-based pain management and clinical standards, moderate to severe postoperative pain in children is common. Inadequate postoperative pain management contributes to poor health outcomes, increased opioid use, and the development of chronic postsurgical pain. Successful postoperative pain management requires regular monitoring and treatment of pain after hospital discharge. Smartphones are nearly ubiquitous, and growing evidence supports their use to overcome barriers to pain care. Computerized clinical decision support systems (CDSS) can improve pain self-management by tracking symptoms over time and offering tailored evidence-informed pain management advice based on standardized algorithms. A comprehensive and sustainable approach is needed to address poorly managed pediatric postoperative pain in the home setting. To address these gaps in care, we are developing "iCanCope with Post-Operative Pain" (or iCanCope PostOp), a smartphone-based CDSS app that provides remote, in-the-moment advice to improve pain and health-related quality of life (HRQL) for adolescents following surgery.
While maintaining a robust reserve of daily necessities is crucial for urban safety, but there is a lack of scientific basis for determining "what to store" and "how much to store." This paper address this gap by classifying and summarizing the emergency materials of urban necessities in Shanghai, and establishing a corresponding reserve list. By constructing an index model of daily necessities reserve, this paper provides a scientific foundation for "what to store." Additionally, the reserve levels of different types of daily necessities are classified and managed, the reserve model of emergency daily necessities is constructed. This approach clarifies the scientific basis for "how much to store," overcoming the problems of subjective factors interference and the potential mismatch between the results of objective weighting method and reality. Furthermore, to better cope with emergencies, countermeasures and suggestions are put forward: optimizing the material structure of emergency reserves, managing the material reserves at different levels, scientifically and reasonably planning the amount of emergency materials, and reducing the cost of reserves and improve the efficiency of emergency reserves.
Disclosed herein is a method for treating renal disease in a subject that involves treating the subject with an effective amount of a compound of the formula (I). The disclosed method can in some embodiments, be used to treat any renal disease involving mitochondrial dysfunction. For example, in some embodiments, the renal disease involves acute kidney injury. As another example, in some embodiments, the renal disease involves diabetic kidney disease. In some embodiments, the renal disease is a glomerular disease (e.g. focal segmental glomerular sclerosis). In some embodiments, the renal disease is a renal vascular disease.
The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs and SSRIs, including with fluoxetine, alone but particularly with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. John's Wort) and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).

Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Patients should be monitored for the emergence of serotonin syndrome.

The concomitant use of fluoxetine with MAOIs intended to treat psychiatric disorders is contraindicated. Fluoxetine should also not be started in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue. All reports with methylene blue that provided information on the route of administration involved intravenous administration in the dose range of 1 mg/kg to 8 mg/kg. No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection) or at lower doses. There may be circumstances when it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a patient taking fluoxetine. Fluoxetine should be discontinued before initiating treatment with the MAOI [see CONTRAINDICATIONS (4.1) and DOSAGE AND ADMINISTRATION (2.9, 2.10)].

If concomitant use of fluoxetine with other serotonergic drugs, i.e., triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, tryptophan, and St. John's Wort is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases.

Treatment with fluoxetine and any concomitant serotonergic agents, should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated.
Participants received Placebo capsule weekly in combination with MTX for 12 weeks. At Week 12, participants were switched from placebo capsule to Tofacitinib 5mg, capsule, orally, BID in combination with MTX plus placebo injection to maintain the blind for 52 weeks.
Will receive intravenous Tranexamic Acid (TXA) 15mg/kg (maximum 1 gram) bolus dose over 10 minutes in the Emergency Center. The subject will also receive an intravenous dose of Tranexamic Acid (TXA) 15mg/kg over 8 hours prior to surgery. Another 15mg/kg dose of Tranexamic Acid (TXA) will be administered over 10 minutes at the time of incision and the final dose (15mg/kg) of Tranexamic Acid (TXA) intravenously over 10 minutes three hours later.